Gilead Revenue Rises on Remdesivir Sales

Gilead Sciences Inc.’s revenue rose 17% in the third quarter, helped by sales of its antiviral drug remdesivir that has become a standard treatment for hospitalized Covid-19 patients. Yet sales of the company’s other drugs […]